Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16

OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March, 2022

---

Commission File Number: 001-37891

AC IMMUNE SA

(Exact name of registrant as specified in its charter)

EPFL Innovation Park

Building B

1015 Lausanne, Switzerland

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

☒

Form 40-F

☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes

☐

No

☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes

☐

No

☒

---

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			AC IMMUNE SA
			By:	/s/ Andrea Pfeifer
				Name:	Andrea Pfeifer
				Title:	Chief Executive Officer
			By:	/s/ Joerg Hornstein
				Name:	Joerg Hornstein
				Title:	Chief Financial Officer
Date:	March 22, 2022

2

---

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated March 22, 2022
99.2		2021 IFRS Consolidated Financial Statements
99.3		2021 Statutory Annual Report
99.4		2021 Compensation Report

3

---